DouglasYeeMD
Oncology • Minneapolis, MNBreast Cancer, Hematologic Oncology
Professor of Medicine Director, Masonic Cancer Center, University of Minnesota
Telehealth Available
Overview of Dr. Yee
Dr. Douglas Yee is an oncologist in Minneapolis, MN and is affiliated with M Health Fairview University of Minnesota Medical Center. He received his medical degree from University of Chicago Division of the Biological Sciences The Pritzker School of Medicine and has been in practice 36 years. Dr. Yee accepts several types of health insurance, listed below. He is one of 88 doctors at M Health Fairview University of Minnesota Medical Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
Masonic Cancer Center, University of Minnesota
420 Delaware Street SE
Minneapolis, MN 55455
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
University of North Carolina HospitalsResidency, Internal Medicine, 1981 - 1985
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1981
Certifications & Licensure
MN State Medical License 1999 - 2025
TX State Medical License 1989 - 2007
NC State Medical License 1984 - 1999- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer Start of enrollment: 2006 Jul 01
- CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery
- Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca Start of enrollment: 2008 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Correction: A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.Katherine Leggat-Barr, Douglas Yee, Erin Duralde, Caroline Hodge, Virginia Borges
Breast Cancer Research and Treatment. 2024-12-20 - Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.Hope S Rugo, Mike Campbell, Christina Yau, A Jo Chien, Anne M Wallace
Breast Cancer Research and Treatment. 2024-12-03 - A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.Katherine Leggat-Barr, Douglas Yee, Erin Duralde, Caroline Hodge, Virginia Borges
Breast Cancer Research and Treatment. 2024-11-12
Lectures
- The DNA Cytosine Deaminase APOBEC3B Promotes Tamoxifen Resistance in ER-Positive Breast CancerAmerican Society of Clinical Oncology(ASCO), Chicago, Illinois - 8/9/2013
- The DNA Cytosine Deaminase APOBEC3B Promotes Tamoxifen Resistance in ER-Positive Breast CancerAmerican Society of Clinical Oncology(ASCO), Los Angeles, California - 8/16/2013
Press Mentions
Meet the Group Making Cancer Trials More Equitable in MinnesotaNovember 13th, 2024- What Black Women Should Know on Metastatic Breast Cancer Awareness DayOctober 16th, 2024
- What Black Women Should Know About Metastatic Breast CancerOctober 14th, 2024
- Join now to see all
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Minnesota Blue Cross Accord
CIGNA Open Access
CIGNA PPO
First Health PPOGreat West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
